Drug Firm Jubilant Life Sciences Gets ANDA Approval for Generics Mycophenolate Mofetil and Rizatriptan

The Indian drug company, Jubilant Life Sciences, has announced in a statement that it has received final approvals for its generics Mycophenolate Mofetil and Rizatriptan from the FDA.

The Indian drug company, Jubilant Life Sciences, has announced in a statement that it has received final approvals for its generics Mycophenolate Mofetil, an immuno-suppressant, and Rizatriptan, used for treatment of migraine, from the Food and Drug Administration (FDA) of the U.S., in the American market.

The drug firm has received final approvals for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil capsules and tablets, manufactured by the company’s U.S. subsidiary branch, Jubilant Cadista Pharmaceuticals Inc., and Rizatriptan tablets made at Jubilant Generics Ltd, Jubilant Life Sciences said in a filing to the Bombay Stock Exchange.

FDA Nods Functional Assessment Technology from Imbio: Boon for COPD
The University of Michigan had developed a new technology ‘Functional Assessment Technology’, which has recently got FDA’s (Food and Drug Administration) clearance.

The approvals are provided for Mycophenolate Mofetil in the strengths of 250 mg capsules and 500 mg tablets. For Rizatriptan tablets, the strengths of 5 mg and 10 mg were given approval. Mycophenolate Mofetil is a generic version of Roche’s Cellcept while Rizatriptan tablets are generics of Merck’s Maxalt tablets.

In a statement released by the Jubilant Life Sciences, it was said that, “The current annualised US market size for Mycophenolate Mofetil USP, 250 mg capsules and 500 mg tablets, is $245 million and for Rizatriptan Tablets 5 mg and 10 mg it is $70 million, as per IMS.”

The company had a total of 781 filings for formulations as of September 30, 2014, of which 322 have been approved in various regions globally. This includes 72 ANDAs filed in the US and 46 dossier filings in Europe, the company said.

LightMix Ebola Zaire Test Gets Approval from US FDA
The Swiss pharmaceutical firm Roche has received an emergency authorization from the US Food and Drug Administration (US FDA) for LightMix Ebola Zaire test.

Source-Medindia

FDA's Prescription Guideline Forces Doctors to Write More Legibly
The Indian Medical Association (IMA) has directed all doctors practicing in Maharashtra to follow the new prescription guidelines put in place by the state Food and Drugs Administration (FDA).

Clinical Trials and Its different Phases
Clinical trials serve as a vital component for improving the treatment of medical conditions as they lead to higher standards of patient care.